Successful use of percutaneous ECMO and intra-aortic balloon support for a rescue valve in valve TAVR procedure in a patient in cardiogenic shock

Alenka Golicnik1*, Matjaz Bunc2, Marko Noc1 and Vojka Gorjup1

1Department for Intensive Internal Medicine, University Medical Center Ljubljana, Slovenia
2Department for Cardiology, University Medical Center Ljubljana, Slovenia

Abstract

Transcatheter aortic valve replacement (TAVR) is becoming an effective treatment method for severe aortic stenosis but can pose severe hemodynamic risk during procedure. Acknowledgement of the risk and a plan for preprocedural hemodynamic stabilization of high-risk patients using advanced hemodynamic support measures is therefore crucial for final success. We report and discuss a case of a patient in cardiogenic shock due to left ventricular failure because of a severe redo biological AVR stenosis that was successfully treated with a rescue valve in valve TAVR under prophylactic pre- and postprocedural percutaneous mechanical support with a combination of VA ECMO and intra-aortic balloon pump (IABP).

Introduction

Transcatheter aortic valve replacement (TAVR) is an effective method for treating severe aortic stenosis in high risk surgical patients that is recently being expanded also to intermediate-risk populations [1-3]. TAVR has also been used as a treatment for the failing bio prostheses as a valve in valve procedure with mortality rates similar to those in redo surgical AVR despite higher surgical risk [4]. However, TAVR procedure can cause profound hemodynamic destabilization in patients at an already high risk of complications. It is therefore crucial that patients with severe left ventricular dysfunction, acute heart failure or cardiogenic shock are hemodynamically stabilized peri procedurally. Veno-arterial (VA) ECMO offers an option of mechanical circulatory support. There is still little evidence on the preprocedural prophylactic use of VA ECMO in critically ill TAVR patients [5]. On the other hand, data is emerging on increased VA ECMO weaning success and increased survival when ECMO is used in combination with intra-aortic balloon pump (IABP) in patients with cardiogenic shock [6]. We report a case of a patient in cardiogenic shock due to left ventricular failure because of a severe redo biological AVR stenosis that was successfully treated with a rescue valve in valve TAVR under prophylactic pre- and postprocedural percutaneous mechanical support with a combination of VA ECMO and IABP.

Case Report

A 56 years old male was admitted to cardiology department due to symptoms of cardiac decompensation that presented as breathlessness on minimal exertion, dizziness and orthopnea. He was in NYHA class III. Past medical history revealed that he had undergone a mechanical AVR in 1992 due to congenital aortic stenosis. In 2014 a mechanical re-AVR was performed because of valve degeneration and an aortic graft was implanted at the same time due to ascending aorta aneurysm. In 2015 he was diagnosed with AVR endocarditis and was reoperated with a biological AVR and aortic graft implantation. Two years later severe aortic regurgitation was observed, and he was reoperated for the fourth time and a new biological AVR (Sorin Perceval L 25 mm) was implanted.

During this hospitalization echocardiography revealed a severe stenosis of biological AVR due to pannus formation (mean gradient 44 mm Hg, AV A 0.4 cm²), a dilated left ventricle (EDD 6 cm) with minimal concentric hypertrophy, a severely reduced left ventricular ejection fraction of 20% (SVi 27 ml/m²) and a moderate postcapillary pulmonary hypertension (sPAP 50 mm Hg). Coronary angiogram was normal (Figures 1 and 2). His surgical risk stratification at that time revealed a Euroscore II of 10.98%. After heart team discussion he was planned for another mechanical re-AVR (Bentall procedure). Due to a higher surgical risk, reduced ejection fraction and young age a protocol for elective heart transplantation listing was started as well. During the course of hospitalization diuretic therapy was intensified and he received levosimendan infusion. In spite of this his condition deteriorated and on day 20 he had a syncope. Sustained VT was observed that resolved spontaneously but patient developed pulmonary edema and cardiogenic shock. He was transferred to ICU where he was intubated and mechanically ventilated, IABP was inserted and he was put on high inotropic and vasopressor support to maintain arterial pressure and organ perfusion. In spite of all these measures patient’s condition deteriorated further, he was hypotensive with a MAP 60 mmHg, a short
Successful use of percutaneous ECMO and intra-aortic balloon support for a rescue valve in valve TAVR procedure in a patient in cardiogenic shock

Golicnik A (2019) Successful use of percutaneous ECMO and intra-aortic balloon support for a rescue valve in valve TAVR procedure in a patient in cardiogenic shock

3.7 l/min/m² with a reduction of filling pressures (CVP 7 mmHg, sPAP 35 mmHg, dPAP 22 mmHg, PWP 13 mmHg). After another 4 hours of stable hemodynamics on low ECMO flow of 1 lpm, ECMO circuit was removed. IABP was removed on the next day. There were no complications on percutaneous approach sites. Echocardiography post procedurally revealed an improvement in LVEF to 30% with a good functioning of positioned aortic valve with a mean transprothetic gradient of 17 mmHg, AV A 2.5 cm², and mild pulmonary hypertension (sPAP 28 mm Hg). He also received levosimendan. Heart failure reversed rapidly, we observed improvement of kidney and liver function. Pleural drainage was performed to improve patient recompensation and on day 5 the patient was successfully extubated and then transferred back to cardiology department after 6 days of ICU stay.

During further hospital stay patient completed protocol for inclusion into heart transplantation list. CRT-D was also implanted, and he was rehabilitated and released into home care with a normal kidney function and in NYHA II class. He is being followed-up regularly and is listed into transplantation waiting list. His latest echocardiography showed a dilated left ventricle (EDD 5.8 cm) with moderately decreased ejection fraction (LVEF 46%), good functioning of prosthetic valve (mean transprothetic gradient 20 mmHg, AV A 2.01 cm², minimal paravalvular leak) and mild pulmonary hypertension (sPAP 29 mmHg) (Figure 3).

Discussion

TAVR seems an attractive treatment option for high risk redo patients as conventional elective redo aortic valve surgery carries an operative mortality risk from 2-7% [8], which rises significantly in the case of hemodynamic instability and left ventricular failure as was the case in our patient in whom another surgical redo AVR would pose an even greater risk as it would be his fifth surgical procedure. Redo resuscitation was needed due to PEA, his kidney and liver function deteriorated, and anuria developed. Swan-Ganz catheterization revealed high right and left filling pressures (CVP 27 mmHg, sPAP 63 mmHg, dPAP 40 mmHg, PWP 40 mmHg) with a low CI of 1.9 L/min/m². As we could not stabilize the patient further treatment options were discussed with heart team and a decision was made to try to achieve patient stabilization with a rescue valve in valve TAVR procedure done under a percutaneously implanted ECMO support in view of high-risk unstable patient in cardiogenic shock.

After transfer to catheterization laboratory right femoral artery and vein were cannulated first with a 15 Fr arterial and 23 Fr venous cannula and patient was connected to ECMO circuit (Cardiohelp, Maquet) [7]. Flow rate was set to 1 lpm. IABP previously placed through a 7 Fr sheath in left femoral artery was removed and an 18 Fr sheath was placed for the TAVI prosthesis delivery. Balloon aortic valvuloplasty was done with Zelos balloon (OptiMed, UK) 20 x 40 mm during 180/min rapid ventricular pacing to predilate the valve. Post predilation there was a loss of arterial pressure pulsatility observed with a MAP of 30 mmHg as there was no significant cardiac output post procedure and ECMO flow was increased to 4 lpm during that time to preserve organ and coronary perfusion. Edwards Sapien 3 26 mm valve was then positioned and deployed. There was an immediate arterial pulsatility restoration with a left ventricular systolic pressure of 110 mmHg after placement of the valve. ECMO flow was reduced slowly back to 1 lpm with preservation of arterial pressure pulsatility and MAP. There was no significant aortic regurgitation observed post procedure. TAVI sheath was removed and percutaneous approach was closed with a combination of Proglide and Angioseal closure systems. IABP was inserted again through left femoral artery and patient was transferred back to ICU on low flow VA ECMO and IABP support.

Immediately after TAVR procedure we observed patient stabilization with massive diuresis ensuing and an increase in CI to

![Figure 1. Coronary angiogram before TAVR. No important coronary lesions. a. LAO CAU (LCA) b. RAO (LCA) c. LAO (RCA)](image1)

![Figure 2. Aortic angiography before TAVR. No aortic regurgitation, degenerated Perceval (Sorin, USA) valve. a. aortic angiography: degenerated Perceval (Sorin) valve. ECMO cannula (arrow) b. Balloon aortic valvuloplasty)

![Figure 3. Step by step TAVR valve in valve. a. Edwards Sapien 3 valve 26 mm. ECMO cannula (arrow). b. Positioning of TAVR device. c. Rapid pacing (180/min) and implantation of Sapien 3 26 mm valve. d. Final valve position with valve upper frame below LM. No regurgitation on aortic angiography. LM and RCA: no compromise of coronary flow)](image2)
surgery is also associated with a prolonged recovery and increased morbidity. As valve in valve TAVR has recently proved feasible [9] and with no different early mortality rates compared to those for surgery in spite of higher preprocedural risk [4] it provides a reasonable and less invasive option in such patients. Recent data also confirm that TAVR is increasingly becoming not only an elective procedure but that nearly 10% of contemporary TAVRs are urgent or emergent and nearly 8% are performed in patients with LV ejection fraction <30% [10]. However, in patients presenting with concomitant cardiogenic shock, TAVR was associated with nearly 33% 30-day and 60% 1-year mortality [11]. Predictors of 30-day mortality in these patients were baseline cardiac output <3.0 l/min, reduced cardiac power index, impaired renal function, mechanical ventilation as well as severe acute kidney injury after TAVR [11]. Pre- and postprocedural hemodynamic stabilization is therefore crucial for TAVR success in these patients.

VA ECMO proved to be a successful bridging therapy for hemodynamic stabilization in cardiogenic shock and there are reports of its use in high risk TAVR patients [12,13] although risk stratification for ECMO use in TAVR patients is still not clear and it was according to a recent review so far used in only a small percentage (4%) of TAVR patients and mostly as emergency rescue strategy in cases of TAVR complications [5]. The outcomes of two series of patients [14,15] in whom ECMO was used as a prophylactic measure in selected high-risk patients were comparable to conventional TAVR patients whereas emergency ECMO in TAVR was associated with significantly lower procedural success and survival [16]. Prophylactic ECMO before TAVR therefore seems a very effective use of mechanical support resources but risk stratification of patients that would benefit from its preprocedural implementation apart from patients in clear cardiogenic shock where TAVR and ECMO both present a rescue strategy is still to be defined, especially as ECMO itself carries significant risk of complications.

Another aspect of hemodynamic stabilization attempt in our report is the use of combination of VA ECMO and IABP, which are two of most commonly used temporary bridging mechanical support devices. Although they represent both ends of cardiac unloading capacity and although IABP was lately somewhat disregarded as an effective mechanical support [17], reports emerge on better survival and VA ECMO weaning success when used in combination with IABP [6]. These observations are hypothesized to be the result of a somewhat different mechanisms of IABP and ECMO cardiac support with IABP reducing or neutralizing some of the unwanted effects of prophylactically used ECMO such as the afterload increase and by increasing coronary perfusion during ECMO support [18]. We believe such strategy is not applicable only to cardiogenic shock patients requiring VA ECMO but also to ECMO supported TAVR patients with severely reduced EF, where IABP could reduce additional afterload increase during hours of ECMO support and could enable an even more gradual and safe weaning of mechanical unloading of the stunned myocardium after ECMO removal.

Conclusion

We conclude that prophylactic percutaneous VA ECMO is an optimal hemodynamic stabilization method for rescue TAVR in cardiogenic shock and it also seems an attractive option for better results in high risk TAVR patients that still need to be stratified according to risk-benefit ratio. Combination of VA ECMO and IABP use might have a place in these patients as well to allow for a smooth myocardial recovery although this strategy still needs to be evaluated and proved in general.

Disclosure

The authors declare that they have no competing interests.

References


Copyright: ©2019 Golicnik A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.